# Safety, Blood Levels and Effects of GW642444

> **NCT00469040** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GW642444M for 14 days

## Key facts

- **NCT ID:** NCT00469040
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-28
- **Primary completion:** 2007-04-16
- **Final completion:** 2007-04-16
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00469040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00469040, "Safety, Blood Levels and Effects of GW642444". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00469040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*